Review
doi: 10.1111/j.1527-3458.2002.tb00220.x.
Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment
Affiliations
- PMID: 12177685
- PMCID: PMC6741668
- DOI: 10.1111/j.1527-3458.2002.tb00220.x
Item in Clipboard
Review
Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment
CNS Drug Rev.
2002 Summer.
Abstract
Ensaculin, a novel benzopyranone substituted with a piperazine moiety, showed memory-enhancing effects in paradigms of passive and conditioned avoidance in both normal and artificially amnesic rodents. It exhibited neuroprotective activities in an NMDA toxicity model and neurotrophic effects in primary cultured rat brain cells. The compound could be characterized as a weak NMDA receptor-operated channel blocker. In receptor-binding studies, ensaculin was found to have high affinities to serotonergic 5-HT(1A) and 5-HT(7) receptors, adrenergic alpha(1), and dopaminergic D(2) and D(3) receptors. Due to its unique pharmacodynamic profile, ensaculin may have potential as an antidementia agent acting on various transmitter systems.
Similar articles
-
Oral post-lesion administration of 5-HT(1A) receptor agonist repinotan hydrochloride (BAY x 3702) attenuates NMDA-induced delayed neuronal death in rat magnocellular nucleus basalis.Neuroscience. 2001;108(4):629-42. doi: 10.1016/s0306-4522(01)00444-4. Neuroscience. 2001. PMID: 11738499
-
Generalization of serotonin (5-HT)1A agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD128,907 and 7-OH-DPAT.Neuropharmacology. 2001 Jun;40(7):899-910. doi: 10.1016/s0028-3908(01)00022-3. Neuropharmacology. 2001. PMID: 11378160
-
Synthesis and pharmacological evaluation of 1-[(1,2-diphenyl-1H-4-imidazolyl)methyl]-4-phenylpiperazines with clozapine-like mixed activities at dopamine D(2), serotonin, and GABA(A) receptors.J Med Chem. 2002 Oct 10;45(21):4655-68. doi: 10.1021/jm020848t. J Med Chem. 2002. PMID: 12361392
-
A review of the neuroprotective properties of the 5-HT1A receptor agonist repinotan HCl (BAYx3702) in ischemic stroke.CNS Drug Rev. 2005 Winter;11(4):379-402. doi: 10.1111/j.1527-3458.2005.tb00055.x. CNS Drug Rev. 2005. PMID: 16614737 Free PMC article. Review.
-
Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex.Curr Pharm Des. 2010;16(5):502-15. doi: 10.2174/138161210790361416. Curr Pharm Des. 2010. PMID: 19909228 Review.
Cited by
-
Coumarin derivatives as acetyl- and butyrylcholinestrase inhibitors: An in vitro, molecular docking, and molecular dynamics simulations study.Heliyon. 2019 Apr 28;5(4):e01552. doi: 10.1016/j.heliyon.2019.e01552. eCollection 2019 Apr. Heliyon. 2019. PMID: 31183424 Free PMC article.
-
Coumarin Derivative Hybrids: Novel Dual Inhibitors Targeting Acetylcholinesterase and Monoamine Oxidases for Alzheimer's Therapy.Int J Mol Sci. 2024 Nov 28;25(23):12803. doi: 10.3390/ijms252312803. Int J Mol Sci. 2024. PMID: 39684512 Free PMC article.
-
Convenient Synthesis of Functionalized Cyclopropa[c]coumarin-1a-carboxylates.Molecules. 2018 Dec 24;24(1):57. doi: 10.3390/molecules24010057. Molecules. 2018. PMID: 30586901 Free PMC article.
-
Non-cholinergic strategies for treating and preventing Alzheimer's disease.CNS Drugs. 2002;16(12):811-24. doi: 10.2165/00023210-200216120-00003. CNS Drugs. 2002. PMID: 12421115 Review.
-
Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.Curr Neuropharmacol. 2014 Jan;12(1):2-36. doi: 10.2174/1570159X113116660047. Curr Neuropharmacol. 2014. PMID: 24533013 Free PMC article.
References
-
- Beal MF, Uhl G, Mazurek MF, Kowall N, Martin GB. Somatostatin: Alterations in the central nervous system in neurological disorders In: Martin GB, Barchas JD, Eds. Neuropeptides in Neurological and Psychiatric Disease. New York : Raven Press, 1986;215–257. - PubMed
-
- Benzi G, Moretti A. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease Eur J Pharmacol 1998;346:1–13. - PubMed
-
- . Anonymous. Two more Alzheimer's drugs fail. Scrip 1999;2436:21.
-
- Chatterjee S, Nöldner M. An aggregate brain cell culture model for studying neuronal degeneration and regeneration. J Neural Transm 1994;44 (Suppl 1): 47–60. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
